Oraxion Therapeutics is a pioneering drug discovery company specializing in rare and orphan diseases. With over 7,000 unique rare diseases affecting approximately 350 million patients worldwide, Oraxion focuses on developing therapeutics for these conditions that currently have limited treatment options. Over 80% of rare diseases have a genetic origin, and nearly 50% primarily affect children.

Oraxion aims to use their technology platform to create innovative therapeutic interventions, improving the quality of life for patients with these diseases. The company's management team includes Mr. Arun B Papaiah as Founder and CEO, Dr.

Aditya Kulkarni as Founder and CSO, Mr. Srinivasan Namala as Founder and Director, and Mr. Tom Johnston as Chief Business Officer.

These experienced individuals bring a wealth of knowledge and expertise to the company. Oraxion's business philosophy centers around addressing the significant knowledge gaps and lack of treatment options for rare diseases. With a growing global rare disease market approaching USD 100 billion and increased awareness surrounding these diseases, Oraxion is at the forefront of developing novel, affordable therapeutic alternatives.

The company employs a platform technology approach, combining material chemistry and discovery biology, to develop robust and specific drug delivery systems. This approach allows Oraxion to target diseases with underlying pathophysiological mechanisms, ensuring the effective and efficient delivery of therapeutics. Currently, Oraxion is focused on developing a diverse pipeline of polymer drugs for rare diseases, such as Niemann-Pick Type C Disorder and Focal Segmental Glomerulosclerosis.

Additionally, the company has undisclosed programs in the works with their partners. By bringing affordable healthcare solutions to patients with rare and orphan diseases, Oraxion Therapeutics aims to make a lasting impact on improving the lives of those with high unmet medical needs